HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

.

HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

University of Utah and Emory University/Veterans Affair Medical Center (VA) conducted a research which concluded that retrovirus associated to chronic fatigue syndrome (CFS) and prostate cancer has been found to be present in four drugs that are used to combat HIV.

The research has raised a hope that if it is found that retrovirus XMRV i. e., Xenotropic murine leukemia virus-related virus causes prostate cancer or CFS; the HIV drugs can prove helpful in curing the same.

Dr. Ila R Singh said that the concluded results were a ray of hope for the patients suffering from prostate cancer and CFS.

The researchers will have to look for a better and magnified understanding of the links between HIV and CFS and prostate cancer for developing drugs that can cure them.

In this research, in cultured human breast cancer and prostate cancer cells, 45 drugs treating HIV were tested for their effectiveness against XMRV.

Raltegravir, L-00870812, Zidovudine and Tenofovir disoproxil fumarate were the drugs tested.

Co-investigator Raymond F Schinazi said that the research revealed that drugs inhibited XMRV at lower levels when used together, which in turn indicate that the virus might restrain the virus from replicating and spreading.


Latest News

Report Shows Large Number of Americans still Prefer Receiving Credit Card Statem
U.S. Big Banks Pass Annual Stress Test
Viacom’s Board will Remain as it is for the Time being, Judge Sets Hearing for J
Crude Stockpiles Drop in the U. S
A New Study Highlights that U. S. Expected to Spend $2.6 Trillion Less than Esti
SolarCity Shares Soar with Tesla's Bid for the Company
The Leave as well as Remain Camps Gathers Pace in Brexit
Oil’s Advance Halts as Market Awaits U.S Stock Pile Data and Brexit Poll
Martin Winterkorn and a Current VW Board Member Under Investigation by Prosecuto
Survey Shows Some Workplace Benefits are Fading with Time
Kimco Realty Corporation Shares Climbed 0.21 Percent Last Week
Sluggish Growth and Inflation is Taking More Time Than Expected Affecting Fed’s